Celltrion Reveals 2030 Ambition Amid 80mg High-Concentration Adalimumab Launch
Korean Firm Continuing To Target Interchangeability Designation For Yuflyma
Celltrion has grand ambitions to grow its portfolio and top line by the start of the next decade, as the firm told the recent Annual J.P. Morgan Healthcare Conference.
